Compare iShares Silver Trust (SLV) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs Zimmer Biomet Holdings Inc — how do they compare? iShares Silver Trust trades at $55 (market cap $29.02B), while Zimmer Biomet Holdings Inc trades at $89.12 (market cap $16.95B). The key difference: iShares Silver Trust is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while iShares Silver Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Silver Trust for 89 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SLV | ZBH | |
|---|---|---|
Market Cap | $29.02B | $16.95B |
Volume | 16,510,334 | 2,505,240 |
52-Week High | $105.57 | $103.98 |
52-Week Low | $42.40 | $79.58 |
Typical Hold Time | 89 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV trades at $55.06, up 2.3% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported $2.17M net income for 2024 despite zero revenue, with total assets surging to $13.41B from $10M in 2023. Recent news highlights silver price volatility driven by Fed policy expectations and Treasury yields.
The outlook is clouded by bearish technicals and macroeconomic pressures on silver, though low debt and asset growth offer stability. Risks include interest rate sensitivity and industrial demand fluctuations, while institutional sentiment remains cautious amid price declines.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
